SCHEMBL10116134

SCHEMBL10116134

Cc1cc(C(=O)NC(C)C)c(C)c(C)c1NC(=O)N1CCC(NS(=O)(=O)C(C)C)CC1

nearest known ligand 0.43

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CCR8 P51685 8/20 0.43
POLB P06746 2/20 0.35
ALOX15 P16050 1/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
GAA P10253 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MAPK1 P28482 1/20 0.34
NPY5R Q15761 1/20 0.34
KDM5B Q9UGL1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10115794 0.88 CCR8 (0.44) CCR8POLBALOX15KMT2AMEN1
SCHEMBL10116135 0.84 CCR8 (0.40) CCR8POLBALOX15KMT2AKDM5B
SCHEMBL10116138 0.84 CCR8 (0.43) CCR8POLBALOX15KMT2AMEN1
SCHEMBL10114925 0.84 GRIA2 (0.35) CCR8POLBKMT2AMEN1
SCHEMBL13204424 0.84 GRIA2 (0.35) CCR8POLBKMT2AMEN1
SCHEMBL10116024 0.80 CCR8 (0.49) CCR8POLBALOX15KMT2AMEN1
SCHEMBL11935496 0.79 MAPK14 (0.39) NPY5R
SCHEMBL13439238 0.79 MAPK14 (0.39) NPY5R
SCHEMBL10116148 0.78 CCR8 (0.47) CCR8KMT2AMEN1GAAL3MBTL1
SCHEMBL10116044 0.77 USP2 (0.48) CCR8KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R CCR8 429/4885POLB 4727/4885ALOX15 865/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R CCR8 394/4885POLB 4751/4885ALOX15 851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.